Evidence map›Paper›PMID 36382117›Full record

ArticleNeurology. Clinical practice2022

Severity of Epilepsy and Response to Antiseizure Medications in Individuals With Multiple Sclerosis: Analysis of a Real-World Dataset.

Mauricio F Villamar, Rani A Sarkis, Page Pennell, Isaac Kohane, Brett K Beaulieu-Jones

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology. Clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mauricio F VillamarThe Warren Alpert Medical School of Brown University, Providence, RI (MFV); Department of Neurology, Brigham and Women's Hospital, Boston, MA (MFV, RAS, PP, BKB-J); Department of Neurology, University of Pittsburgh Medical Center, PA (PP); and Department of Biomedical Informatics (IK, BKB-J), Harvard Medical School, Boston, MA.
Rani A SarkisThe Warren Alpert Medical School of Brown University, Providence, RI (MFV); Department of Neurology, Brigham and Women's Hospital, Boston, MA (MFV, RAS, PP, BKB-J); Department of Neurology, University of Pittsburgh Medical Center, PA (PP); and Department of Biomedical Informatics (IK, BKB-J), Harvard Medical School, Boston, MA.
Page PennellThe Warren Alpert Medical School of Brown University, Providence, RI (MFV); Department of Neurology, Brigham and Women's Hospital, Boston, MA (MFV, RAS, PP, BKB-J); Department of Neurology, University of Pittsburgh Medical Center, PA (PP); and Department of Biomedical Informatics (IK, BKB-J), Harvard Medical School, Boston, MA.
Isaac KohaneThe Warren Alpert Medical School of Brown University, Providence, RI (MFV); Department of Neurology, Brigham and Women's Hospital, Boston, MA (MFV, RAS, PP, BKB-J); Department of Neurology, University of Pittsburgh Medical Center, PA (PP); and Department of Biomedical Informatics (IK, BKB-J), Harvard Medical School, Boston, MA.
Brett K Beaulieu-JonesThe Warren Alpert Medical School of Brown University, Providence, RI (MFV); Department of Neurology, Brigham and Women's Hospital, Boston, MA (MFV, RAS, PP, BKB-J); Department of Neurology, University of Pittsburgh Medical Center, PA (PP); and Department of Biomedical Informatics (IK, BKB-J), Harvard Medical School, Boston, MA.
Brown University · USUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Epilepsy is an important comorbidity that affects outcomes for people with multiple sclerosis (MS). However, it is unclear whether seizure severity among individuals with coexistence of MS and epilepsy (MS + E) is higher than in those with other focal epilepsies. Our goal was to compare the overall severity of epilepsy in individuals with MS + E vs those with focal epilepsy without MS (E - MS), as defined by seizure-related health care utilization, frequency and duration of status epilepticus, and frequency of antiseizure medication (ASM) regimen changes. Methods: In this hypothesis-generating study, we analyzed a US commercial nationwide deidentified claims data set with >86 million individuals between January 1, 2008, and August 31, 2019. Using validated algorithms, we identified adults with E - MS and those with MS + E. We compared the number and length of seizure-related hospital admissions, the number of claims and unique days with claims for status epilepticus, and the rates of ASM regimen changes between the MS + E and E - MS groups. Results: During the study period, 66,708 individuals with E - MS and 537 with MS + E had ≥2 years of coverage after their initial diagnosis of epilepsy. There was no difference between the MS + E and E - MS groups in the percentage of individuals admitted for seizures and/or status epilepticus. However, MS + E with seizure-related admissions had more admissions and longer hospital stays than those with E - MS. MS + E who experienced status epilepticus had more unique days with status epilepticus claims compared with E - MS. MS + E were more likely to have ASM regimen changes in 2 years after the initial diagnosis of epilepsy and had more ASM changes during 2 years compared with E - MS. Among individuals with MS + E, there were no differences in our measures of seizure severity for those treated with sodium channel blockers/modulators vs other ASM classes. Discussion: This study supports the notion that individuals with MS + E can have more severe epilepsy than those with E - MS. Seizure severity among individuals with MS + E treated with sodium channel blockers/modulators vs other ASM classes shows no significant differences. Classification of Evidence: This study provides Class III evidence that individuals with MS + E can have more severe epilepsy than those with E - MS.

Identifiers

PMID36382117
PMCPMC9647818
OpenAlexW4281398414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.